Uncategorized
FDA flags concerns for AstraZeneca’s camizestrant, Truqap ahead of advisory committee meeting
The FDA has released briefing documents detailing its concerns for AstraZeneca’s cancer drugs camizestrant and Truqap ahead of an upcoming advisory committee meeting, the first such gathering in about nine months.